Research

BPC-157 human trials 2026: the first US placebo study

BPC-157 human trials are finally starting in the US. What the new Arkansas study will test, when results could land, and what human data exists today.

SafePeptideUseSeptember 28, 20265 min read

Key takeaways

The University of Arkansas has registered a randomized, placebo controlled trial of BPC-157 injections after rotator cuff surgery. It is the first of its kind in the United States.
The trial is small (20 to 30 people), is not recruiting yet, and plans to start in January 2027. No results exist yet.
Every human BPC-157 study published so far is a tiny pilot or chart review with no comparison group, so human evidence is still limited and weak.
An FDA advisory panel voted 8 to 6 in July to let pharmacies compound BPC-157, but the FDA has not acted on that vote, and BPC-157 is still banned in tested sport.
A registered trial is a plan to collect data, and until results are published nobody knows if BPC-157 works or is safe in people.

Is there a human trial for BPC-157?

Yes, and this week it finally got noticed. BPC-157 human trials have been almost nonexistent for years. Now the University of Arkansas has registered a randomized, controlled trial of BPC-157 injections after rotator cuff surgery, the first of its kind in the United States.

The listing went up on ClinicalTrials.gov on September 3, 2026 under the number NCT07803250. It sat quietly until September 25 and 26, when posts about it took off on X and landed near the top of the Biohackers subreddit. We pulled the registry record so you can see what the study will and will not tell us.

The short version: this is a real step forward, and it is also a small pilot that has not enrolled anyone yet.

Sources:s1

What will the University of Arkansas BPC-157 trial test?

It will test whether daily BPC-157 shots help a repaired shoulder tendon heal and get strong again. People who have an arthroscopic rotator cuff repair at UAMS Medical Center in Little Rock will be randomly assigned to BPC-157 or a saltwater (saline) injection, given under the skin once a day for 90 days.

Here is the design as the registry lists it:

Detail	What the registry says
Sponsor	University of Arkansas
Phase	Phase 1 pilot
Size	20 patients in the summary, 30 in the enrollment field
Blinding	Patients, surgeons, investigators and assessors all blinded
Treatment	Daily subcutaneous BPC-157 or saline for 90 days after surgery
Main measure	Shoulder strength with a handheld dynamometer at 12 weeks and 5 months
Other measures	MRI of tendon healing, range of motion, patient questionnaires, blood markers of collagen turnover and inflammation

Two things are missing or muddled. The record does not list a BPC-157 dose. It also describes the control group two ways, once as saline shots and once as no treatment at all. Details like these often get cleaned up before a study starts, so treat them as open questions.

The entry rules are fairly strict. Adults need a full thickness tear under 2.5 cm and a BMI of 20 to 34.9. People with diabetes or autoimmune disease, anyone on hormone or testosterone therapy in the past year, and anyone with a platelet rich plasma shot in that shoulder in the past year are excluded.

Sources:s1

When will BPC-157 human trial results come out?

Not before late 2027 at the earliest. The registry lists the study as not yet recruiting, with an estimated start of January 1, 2027 and an estimated primary completion of August 1, 2027.

Those are estimates. Recruiting surgical patients often runs slower than planned, and after the last shoulder is measured the team still has to analyze the data and publish it. Some posts on X put first data in early 2028, which fits that pattern.

There is one more trial to watch. Hudson Biotech is running a larger controlled phase 2 study of BPC-157 in 120 people with grade II hamstring strains, using daily shots for 14 days. That one has been recruiting since February 2, 2026, at Peking University Shenzhen Hospital in China, with primary completion estimated for February 2027. So the Arkansas study is the first in the US, while the hamstring study may report sooner.

Sources:s1, s2

What human data on BPC-157 exists right now?

Very little, and none of it comes from a controlled trial. Two reviews from 2025 and 2026 count only three small human pilot studies, and all three come from private clinics without a comparison group. On our evidence scale that is limited human data at best, and much of it reads closer to anecdotal.

Knee pain, 2021. A chart review from one Florida clinic phoned 16 patients who had BPC-157 injected into the knee, some with thymosin beta 4. Fourteen said their pain improved. There was no control group and no standard pain scale, so this is weak limited human evidence.
Interstitial cystitis, 2024. Twelve women with bladder pain got a single 10 mg injection into the bladder wall during cystoscopy. Ten reported complete relief. No group, so again weak limited human evidence.
IV safety, 2025. Two adults received 10 mg and then 20 mg by IV infusion, with no side effects or blood test changes reported. Two people cannot establish safety.

An older oral BPC-157 safety study in 42 volunteers was registered in Mexico in 2015, but no results were ever posted to the registry.

The animal record is much larger, especially for tendon and muscle healing, and that is why a rotator cuff trial makes sense. A 2026 UCLA review in the American Journal of Sports Medicine found that 67 percent of the peptide studies it included used animals, and concluded the claimed human benefits remain unproven. For the full picture on the compound itself, see our BPC-157 entry.

Sources:s3, s4, s5, s6, s7, s8, s9

Is BPC-157 FDA approved in 2026?

No. BPC-157 is an investigational compound with no FDA approval for any use, and the Arkansas registry says so plainly.

The question is still open too. On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, in favor of adding BPC-157 to the list of bulk substances that 503A pharmacies may compound. The FDA had framed that review around ulcerative colitis. The vote is advisory, and a September 25 analysis in Drug Topics notes compounding it remains technically unlawful until the FDA finishes formal rulemaking. We walked through the votes in our FDA peptide compounding update.

If you compete in tested sport, BPC-157 sits in the S0 non approved substances class of the WADA list, so it is banned at all times.

Sources:s10, s11, s12, s13

What does this mean if you use BPC-157?

Info

It means the question you care about, does it work in people, is finally being tested properly. The answer is at least a year away.

A few practical points while we wait:

Quality is still on you. BPC-157 bought online comes from unregulated sellers. A trial result will only describe the product used in that trial, and it tells you nothing about what is in your vial. Our guide to reading a COA and our post on why a COA matters show what to check.
Stacks are further behind. The trial tests BPC-157 alone. The popular Wolverine stack, BPC-157 combined with TB-500, has no controlled human data as a combination.
Surgery changes the math. If you are heading into an operation, tell your surgeon about any peptide you use. The trial screens out people with diabetes, autoimmune disease or recent hormone therapy, so even a good result will tell those groups very little.
Clean technique matters. If you inject, our reconstitution guide and injection technique guide cover sterile handling.

We will update this post when the Arkansas study starts recruiting and when either trial reports. This is education, not medical advice, and decisions about treatment belong with a clinician.

Sources:s1, s13

Sources

[s1]University of Arkansas, via ClinicalTrials.gov (2026). Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery (NCT07803250). other link
[s2]Hudson Biotech, via ClinicalTrials.gov (2026). BPC 157 for Acute Hamstring Muscle Strain Repair (NCT07437547). other link
[s3]McGuire FP et al., Current Reviews in Musculoskeletal Medicine (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. review link
[s4]Yuan C et al., International Journal of Molecular Sciences (2026). From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. review link
[s5]Lee E, Padgett B, Alternative Therapies in Health and Medicine (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. case report link
[s6]Lee E, Walker C, Ayadi B, Alternative Therapies in Health and Medicine (2024). Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. case report link
[s7]Lee E, Burgess K, Alternative Therapies in Health and Medicine (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. case report link
[s8]PharmaCotherapia d.o.o., via ClinicalTrials.gov (2015). PCO-02 Safety and Pharmacokinetics Trial (NCT02637284). other link
[s9]Tewari K et al., American Journal of Sports Medicine (2026). Peptide Supplements and Their Therapeutic Applications in Sports Medicine. review link
[s10]U.S. Food and Drug Administration (2026). July 23 to 24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. regulatory link
[s11]ABC News (2026). FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list. other link
[s12]Drug Topics (2026). Pharmacy Law Lowdown: FDA's Evaluation of Peptides. other link
[s13]U.S. Anti-Doping Agency (USADA). BPC-157: Experimental Peptide Creates Risk for Athletes. regulatory link